JNJ Johnson & Johnson Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NYSE: JNJ
  4. Earnings
?
Relative Growth: Rel. Growth: 48
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 77

EPS in 2026 (TTM): $6.68

Last Report Period Date: Sep 27, 2026

As of October this year, based on Johnson & Johnson's most recent financial report, the company's trailing twelve months EPS is $6.68. Johnson & Johnson's earnings per share in 2025 was reported at $11.13, marking a rise from $5.84 in 2024. Johnson & Johnson's EPS for the quarterly period ending on Sep 27, 2026 came in at $0.09.

JNJ earnings history

Historical annual and quarterly earnings per share (EPS) data for Johnson & Johnson
EPS (TTM)
$6.68
EPS Growth YoY (Quarterly)
-95.8%
EPS (Quarterly)
$0.09
EPS Growth (Quarterly)
-96.1%

The yearly earnings per share during 2025 was $11.13, a rise of 90.6% compared to $5.84 recorded in 2024. The quarterly earnings per share for the period ending Sep 27, 2026, was $0.09, showing a 95.8% decline compared to the same quarter last year. The trailing twelve months EPS for JNJ is $6.68 as of September 2026. Johnson & Johnson's full-year EPS for 2024 was $5.84, a 57.9% decline compared to the previous year.

JNJ EPS vs price chart

JNJ EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-95.8%
EPS growth YoY
90.6%
EPS growth 3Y avg
17.7%
EPS growth 5Y avg
14.8%

In the past 12 months, Johnson & Johnson has recorded an earnings per share growth rate of -95.8% (YoY, quarterly). Across the past three years, the company had an average EPS annual growth rate of 17.7% per year. In the last five years, the company had an average annual EPS growth of 14.8%. When assessed over a ten-year period, JNJ's average EPS annual growth was 7.2%.

JNJ Earnings Waterfall

Breakdown of revenue, profit and net income for Johnson & Johnson

JNJ Earnings vs Peers

What are the earnings of JNJ compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
NVS Novartis AG 22.66 21.8% 31.2% 15.2%
MDT Medtronic Plc 23.47 3.3% 9.8% 6.9%
SYK Stryker Corp 31.71 8% 10.9% 14.8%
ABT Abbott Laboratories 33.23 -51.4% -1.8% 8.2%
JNJ Johnson & Johnson 39.36 90.6% 17.7% 14.8%
PFE Pfizer Inc 39.55 -3.5% -37.4% -3.7%
LLY Lilly(Eli) & Company 42.88 95.6% 49.2% 27.5%
MRK Merck & Co Inc 113.69 8% 8.4% 21.2%
GILD Gilead Sciences Inc N/A 1,700% 23.2% 132.8%

All data is based on quarterly TTM periods, unless otherwise specified.